Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)

被引:41
作者
Ganjoo, Kristen [1 ]
Hong, Fangxin [2 ]
Horning, Sandra J. [3 ]
Gascoyne, Randy D. [4 ]
Natkunam, Yasodha [1 ]
Swinnen, Lode J. [5 ]
Habermann, Thomas M. [6 ]
Kahl, Brad S. [7 ]
Advani, Ranjana H. [1 ]
机构
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Mayo Clin, Rochester, MN USA
[7] Univ Wisconsin, Madison, WI USA
关键词
Lymphoma and Hodgkin disease; chemotherapeutic approaches; immunotherapeutic approaches; NON-HODGKIN-LYMPHOMA; ANGIOGENIC GROWTH-FACTORS; PHASE-2; TRIAL; EXPRESSION; CHOP; INSTITUTION; PROGNOSIS; RITUXIMAB; VEGF;
D O I
10.3109/10428194.2013.816700
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peripheral T-cell lymphoma (PTCL) and natural killer (NK) cell lymphoma have poor survival with conventional cytotoxic chemotherapy. Because angiogenesis plays an important role in the biology of PTCL, a fully humanized anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab (A), was studied in combination with standard cyclosphosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy (ACHOP) to evaluate its potential to improve outcome in these patients. Patients were treated with 6-8 cycles of ACHOP followed by eight doses of maintenance A (15 mg/kg every 21 days). Forty-six patients were enrolled on this phase 2 study from July 2006 through March 2009. Forty-four patients were evaluable for toxicity and 39 were evaluable for response, progression and survival. A total of 324 cycles (range: 2-16, median 7) were administered to 39 evaluable patients and only nine completed all planned treatment. The overall response rate was 90% with 19 (49%) complete response/complete response unconfirmed (CR/CRu) and 16 (41%) a partial response (PR). The 1-year progression-free survival (PFS) rate was 44% at a median follow-up of 3 years. The median PFS and overall survival (OS) rates were 7.7 and 22 months, respectively. Twenty-three patients died (21 from lymphoma, two while in remission). Grade 3 or 4 toxicities included febrile neutropenia (n = 8), anemia (n = 3), thrombocytopenia (n = 5), congestive heart failure (n = 4), venous thrombosis (n = 3), gastrointestinal hemorrhage/perforation (n = 2), infection (n = 8) and fatigue (n = 6). Despite a high overall response rate, the ACHOP regimen failed to result in durable remissions and was associated with significant toxicities. Studies of novel therapeutics are needed for this patient population, whose clinical outcome remains poor.
引用
收藏
页码:768 / 772
页数:5
相关论文
共 31 条
[1]   Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial [J].
Advani, Ranjana H. ;
Hong, Fangxin ;
Horning, Sandra J. ;
Kahl, Brad S. ;
Manola, Judith ;
Swinnen, Lode J. ;
Habermann, Thomas M. ;
Ganjoo, Kristen .
LEUKEMIA & LYMPHOMA, 2012, 53 (04) :718-720
[2]  
[Anonymous], 2011, ISRN HEMATOL
[3]   The aggressive peripheral T-cell lymphomas: 2012 Update on diagnosis, risk stratification, and management [J].
Armitage, James O. .
AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (05) :512-519
[4]   Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma [J].
Bertolini, F ;
Paolucci, M ;
Peccatori, F ;
Cinieri, S ;
Agazzi, A ;
Ferrucci, PF ;
Cocorocchio, E ;
Goldhirsch, A ;
Martinelli, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) :504-509
[5]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[6]  
Coiffier C, 2010, BLOOD S1, V116
[7]   Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01 [J].
d'Amore, Francesco ;
Relander, Thomas ;
Lauritzsen, Grete F. ;
Jantunen, Esa ;
Hagberg, Hans ;
Anderson, Harald ;
Holte, Harald ;
Osterborg, Anders ;
Merup, Mats ;
Brown, Peter ;
Kuittinen, Outi ;
Erlanson, Martin ;
Ostenstad, Bjorn ;
Fagerli, Unn-Merete ;
Gadeberg, Ole V. ;
Sundstrom, Christer ;
Delabie, Jan ;
Ralfkiaer, Elisabeth ;
Vornanen, Martine ;
Toldbod, Helle E. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (25) :3093-3099
[8]   The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells [J].
de Leval, Laurence ;
Rickman, David S. ;
Thielen, Caroline ;
de Reynies, Aurelien ;
Huang, Yen-Lin ;
Delsol, Georges ;
Lamant, Laurence ;
Leroy, Karen ;
Briere, Josette ;
Molina, Thierry ;
Berger, Francoise ;
Gisselbrecht, Christian ;
Xerri, Luc ;
Gaulard, Philippe .
BLOOD, 2007, 109 (11) :4952-4963
[9]  
Dupuis J, 2011, BLOOD S1, V118
[10]   Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis [J].
Ganjoo, Kristen N. ;
An, Caroline S. ;
Robertson, Michael J. ;
Gordon, Leo I. ;
Sen, Joy A. ;
Weisenbach, Jill ;
Li, Shuli ;
Weller, Edie A. ;
Orazi, Attilio ;
Horning, Sandra J. .
LEUKEMIA & LYMPHOMA, 2006, 47 (06) :998-1005